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telephone has been validated. RESULTS: Mean age: 43
years. Sex ratio: 84% men, 16% women, this being in
line with the ratio of users of the SSP. In 54% of our sam-
ple, the period of homelessness was longer than 2 years;
92% were single, 64% had maintained contacts with
their family and 36% declared they had no income. 70%
of those questioned had a score of 17 or higher on the
CES-D scale, indicative of depressive symptoms, mean
score: 22.4; the prevalence of possible depression was
69% and that of probable was 60%. Although no signifi-
cant difference was seen in terms of the duration of
homelessness, two peaks were nonetheless observed: at
28 for those on the street for more than one month and
less than 6 months, and 22.8 for those homeless for more
than two years. CONCLUSION: By “turning the spot-
light” on a poorly understood population, this study pro-
vides relevant results, which demonstrate the need to act
very rapidly to help these populations living in consider-
able need, before the homeless sink into a state of perma-
nent poverty.
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OBJECTIVES: This study compares the one-year direct
schizophrenia-related treatment costs, mental health care
costs and total health care costs of uncontrolled schizo-
phrenia patients initiated on olanzapine versus risperi-
done. METHODS: The integrated medical and pharmacy
claims of a large, geographically diverse, commercially
insured population were used to conduct this analysis.
Patients who initiated treatment with either olanzapine
or risperidone and had one inpatient or two outpatient
services for schizophrenia within 30 days prior to initia-
tion of drug of interest were included in this analysis.
Treatment course and associated schizophrenia-related,
mental health care and total health care costs during the
subsequent 12-month period were examined using uni-
variate and multivariate methods. RESULTS: Four hun-
dred thirty-one (431) patients initiated on risperidone
and 142 initiated on olanzapine met inclusion criteria.
The mean dose was 4.34 and 11 for risperidone and
olanzapine patients, respectively. During the one-year pe-
riod after initiation of drug of interest, olanzapine pa-
tients (compared with risperidone patients) were less
likely to be hospitalized and had shorter mean length of
hospital stays for schizophrenia-related causes, mental
health care causes and all causes. Although pharmaceuti-
cal costs were significantly higher, medical costs were sig-
nificantly lower for patients on olanzapine compared to
those on risperidone. Univariate and multivariate analy-
ses (controlling for potential confounding factors such as
patient demographics, disease severity and comorbidities)
consistently demonstrated that olanzapine patients had
significantly lower schizophrenia-related costs ($2,839 less,
p  0.05), lower mental health care costs ($3,744 less, p 
0.005) and lower total health care costs ($4,674 less, p 
0.001) than those patients initiated on risperidone. CON-
CLUSIONS: The findings revealed significant differences
between olanzapine and risperidone in the treatment of
uncontrolled schizophrenics in clinical practice. Olanza-
pine patients incurred lower costs (lower schizophrenia-
related, mental health care and total health care costs).
The lower costs were inpatient driven by fewer hospital-
izations and shorter length of hospital stays in the olanza-
pine treatment group.
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OBJECTIVE: To compare health care expenditures of
treatment with SNRIs and SSRIs in depressed patients
with or without anxiety. METHOD: Using administra-
tive claims from the MEDSTAT MarketScan database,
we identified patients with a new episode of depression
enrolled in a participating health plan from 1994 to
1998. Patients included for analysis had both a diagnosis
of depression (ICD-9-CM criteria) and a prescription for
either an SNRI (venlafaxine [n  290], venlafaxine XR
[n  63]) or an SSRI (fluoxetine [n  2854], paroxetine
[n  1772], sertraline [n  2580], fluvoxamine [n 
124]) antidepressant. RESULTS: The SNRIs (n  353)
had lower inpatient non–mental health costs ($206 vs
$472; P  0.02) and lower antidepressant medication
costs ($302 vs $338; P  0.01) compared with the SSRIs
(n  7330). In particular, venlafaxine (n  290) costs
were lower than fluoxetine (n  2854) costs ($281 vs
$395; P  0.05). Among patients with depression and
anxiety, SNRIs (n  219) had lower inpatient non–men-
tal health costs ($273 vs $635; P  0.04) and lower anti-
depressant medication costs ($304 vs $350; P  0.01)
than SSRIs (n  4351). Among depressed patients with-
out anxiety, SNRIs (n  134) had lower inpatient non–
mental health costs ($96 vs $234; P  0.05) and lower
inpatient mental health costs among users of inpatient
mental health services ($2,301 vs $4,847; P  0.02) rela-
tive to SSRIs (n  2979). CONCLUSION: Patients re-
ceiving SNRIs appear to have lower health care expendi-
tures in some areas compared with SSRIs among depressed
patients with or without anxiety. Further research is
needed to determine whether patients treated with SNRIs
can be shown to accrue more favorable economic bene-
fits over time relative to patients treated with SSRIs.
